Gastroenterology
Volume 142, Issue 1 , Pages 63-70.e5 , January 2012

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

  • Edouard Louis

      Affiliations

    • Centre Hospitalier Universitaire de Liège, Liège, Belgium
    • Corresponding Author InformationReprint requests Address requests for reprints to: Prof. Edouard Louis, Service d'Hépato-Gastroentérologie et d'Oncologie Digestive, CHU de Liège, Sart Tilman, 4000 Liège, Belgium. fax: (32) 43667889
    • ,
  • Jean–Yves Mary

      Affiliations

    • INSERM U717, Biostatistics and Clinical Epidemiology, Université Paris Diderot-Paris 7, Paris, France
    • ,
  • Gwenola Vernier–Massouille

      Affiliations

    • Université Lille Nord de France and CHRU Lille, Lille, France
    • ,
  • Jean–Charles Grimaud

      Affiliations

    • Hôpital Nord, Centre d'Investigation Clinique Marseille Nord, Université Méditerranée, Marseille, France
    • ,
  • Yoram Bouhnik

      Affiliations

    • Hôpital Beaujon, Université Paris Diderot-Paris 7, Paris, France
    • ,
  • David Laharie

      Affiliations

    • INSERM U853, Université Bordeaux 2, Bordeaux, France
    • ,
  • Jean–Louis Dupas

      Affiliations

    • Hôpital Nord, Amiens, France
    • ,
  • Hélène Pillant

      Affiliations

    • Hôpital Henri Mondor, Créteil, France
    • ,
  • Laurence Picon

      Affiliations

    • Hôpital Trousseau, Tours, France
    • ,
  • Michel Veyrac

      Affiliations

    • Hôpital Saint-Eloi, Montpellier, France
    • ,
  • Mathurin Flamant

      Affiliations

    • Hôtel Dieu, Nantes, France
    • ,
  • Guillaume Savoye

      Affiliations

    • Hôpital Charles Nicolle, Université de Rouen, Rouen, France
    • ,
  • Raymond Jian

      Affiliations

    • Hôpital Européen Georges Pompidou, Paris, France
    • ,
  • Martine DeVos

      Affiliations

    • Faculty of Medicine and Health Science, University of Ghent, Ghent, Belgium
    • ,
  • Raphaël Porcher

      Affiliations

    • INSERM U717, Biostatistics and Clinical Epidemiology, Université Paris Diderot-Paris 7, Paris, France
    • ,
  • Gilles Paintaud

      Affiliations

    • Université François Rabelais de Tours, Tours, France
    • ,
  • Eric Piver

      Affiliations

    • Hôpital Trousseau, Tours, France
    • ,
  • Jean–Frédéric Colombel

      Affiliations

    • Université Lille Nord de France and CHRU Lille, Lille, France
    • ,
  • Marc Lemann

      Affiliations

    • Hôpital Saint-Louis, Université Paris Diderot-Paris 7, Paris, France
    • ,
  • Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives

Received 19 February 2011 ,Accepted 10 September 2011.

References 

  1. Hanauer S , Feagan B , Lichtenstein G , et al.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial . Lancet . 2002;359:1541–1549
  2. Colombel J , Sandborn W , Rutgeerts P , et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial . Gastroenterology . 2007;132:52–65
  3. Schreiber S , Khaliq-Kareemi  , Lauwrance I , et al.  Maintenance therapy with certolizumab pegol for Crohn's disease . N Engl J Med . 2007;357:239–250
  4. Bodger K . Economic implications of biological therapies for Crohn's disease: review of infliximab . Pharmacoeconomics . 2005;23:875–888
  5. Bodger K , Kikuchi T , Hughes D . Cost-effectiveness of biological therapy for Crohn's disease (Markov cohort analyses incorporating United Kingdom patient-level cost data) . Aliment Pharmacol Ther . 2009;30:265–274
  6. Siegel CA , Marden SM , Persing SM , et al.  Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis . Clin Gastroenterol Hepatol . 2009;7:874–881
  7. Toruner M , Loftus E , Harmsen W , et al.  Risk factors for opportunistic infections in patients with inflammatory bowel disease . Gastroenterology . 2008;134:929–936
  8. Kane SV , Aquah LA . Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy . Am J Gastroenterol . 2009;104:228–233
  9. Best W , Becktel JM , Singleton JW , et al.  Development of a Crohn's disease activity index . Gastroenterology . 1976;70:439–444
  10. Mary JY , Modigliani R . Development and validation of a Crohn's disease endoscopic index: a prospective multicentric study . Gut . 1989;30:983–989
  11. Ternant D , Mulleman D , Degenne D , et al.  An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab . Ther Drug Monit . 2006;28:169–174
  12. Van Assche G , Magdelaine-Beuzelin C , D'Haens G , et al.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial . Gastroenterology . 2008;134:1861–1868
  13. Schoenfeld DA . Sample-size formulation for the proportional-hazards regression model . Biometrics . 1983;39:499–503
  14. Kaplan EL , Meier P . Nonparametric estimation for incomplete observations . J Am Stat Assoc . 1958;53:457–481
  15. Cox DR . Regression models and life-tables (with discussions), series B . J R Stat Soc . 1972;34:184–192
  16. White IR , Royston P . Imputing missing covariate values for the Cox model . Stat Med . 2009;28:1982–1998
  17. Grambsch P , Therneau T . Proportional hazards tests and diagnostics based on weighted residuals . Biometrika . 1994;81:515–526
  18. Gönen M , Heller G . Concordance probability and discriminatory power in proportional hazards regression . Biometrika . 2005;92:965–970
  19. Efron B , Tibshirani RJ . An introduction to the bootstrap . In: New York, NY: Chapman & Hall; 1990;p. 17
  20. Siegel S . Nonparametric statistics for the behavioral sciences . In: New York, NY: McGraw-Hill; 1956;p. 75–83
  21. Gisbert JP , Panes J . Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review . Am J Gastroenterol . 2009;104:760–767
  22. Maser EA , Villela R , Silverberg MS , et al.  Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease . Clin Gastroenterol Hepatol . 2006;4:1248–1254
  23. Farrell RJ , Alsahli L , Jeen YT , et al.  Hydrocortisone intravenous premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial . Gastroenterology . 2003;124:917–924
  24. Brocq O , Millasseau E , Albert C , et al.  Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis . Joint Bone Spine . 2009;76:350–355
  25. Baraliakos X , Listing J , Rudwaleit M , et al.  Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis . J Rheumatol . 2007;34:510–515
  26. Laharie D , Chanteloup E , Chabrun E , et al.  The tolerance and efficacy of a postponed retreatment with infliximab in Crohn's disease primary responders . Aliment Pharmacol Ther . 2009;29:1240–1248
  27. Domènech E , Zabana Y , Mañosa M , et al.  Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen . J Clin Gastroenterol . 2010;44:34–37
  28. Tanaka Y , Takeuchi T , Mimori T , et al.  Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study . Ann Rheum Dis . 2010;69:1286–1291

 This article has an accompanying continuing medical education activity on page e31. Learning Objective: Upon completion of this exercise, successful learners will be able to assess the risk of relapse and the response to potential re-treatment in Crohn's disease patients in whom infliximab treatment would be stopped after prolonged stable remission under combined therapy with antimetabolite and infliximab.

 Conflicts of interest The authors disclose the following: E.L. has received consultancy fees from Schering-Plough, Abbott Laboratories, MSD, Ferring Pharmaceuticals, Shire, Millennium Pharmaceuticals, and UCB; research or educational grants from MSD, Schering-Plough, AstraZeneca, and Abbott Laboratories; and lecture fees from Abbott Laboratories, AstraZeneca, Ferring Pharmaceuticals, MSD, Schering-Plough, Falk, Menarini, Chiesi, and Nycomed. Y.B. has received consultancy fees and lecture fees from Norgine, Abbott Laboratories, Schering-Plough, and Ferring Pharmaceuticals. D.L. has received consultancy fees from Norgine and Ferring Pharmaceuticals and has received lecture fees from Norgine, Ferring Pharmaceuticals, Abbott Laboratories, and Schering-Plough. G.S. has received lecture fees from Abbott Laboratories and Schering-Plough. M.D. has received an educational grant from Schering-Plough. G.P. has received consultancy fees from Roche and LFB and has received lecture fees from Janssen-Cilag. J.-F.C. has received consulting fees from Abbott Laboratories, ActogeniX, Albireo Pharma, Amgen, AstraZeneca, Bayer AG, Biogen Idec, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Cellerix, Centocor, ChemoCentryx, Cosmo Technologies, Danone Research, Elan Pharmaceuticals, Genentech, Giuliani SpA, Given Imaging, GlaxoSmithKline, Hutchison MediPharma, Merck Sharp & Dohme Corp, Millennium Pharmaceuticals (now Takeda), Neovacs, Ocera Therapeutics, Pfizer, Shire Pharmaceuticals, Prometheus Laboratories, Sanofi-Aventis, Schering-Plough, Synta Pharmaceuticals Corp, Teva, Therakos, UCB Pharma, and Wyeth; has served on advisory committees for Abbott Laboratories, Centocor, Danone Research, Elan Pharmaceuticals, Merck Sharp & Dohme, Millennium Pharmaceuticals (now Takeda), Schering-Plough, and UCB Pharma; has received speaking fees from Abbott Laboratories, Centocor, Elan Pharmaceuticals, Given Imaging, Merck Sharp & Dohme Corp, Otsuka America Pharmaceutical, Schering-Plough, Shire Pharmaceuticals, Tillotts Pharma, and UCB Pharma; and has received grant support from Abbott Laboratories, AstraZeneca, Ferring Pharmaceuticals, Merck Sharp & Dohme Corp, Schering-Plough, and UCB Pharma. The remaining authors disclose no conflicts.

 Funding The GETAID received unrestricted study grants from the Association François Aupetit and the Société Nationale Française de Gastroentérologie.

PII: S0016-5085(11)01293-5

doi: 10.1053/j.gastro.2011.09.034

Gastroenterology
Volume 142, Issue 1 , Pages 63-70.e5 , January 2012

Article Tools

* Image Usage & Resolution